Manuscripts
Showing 1543 manuscripts.
HIV drug development: the next 25 years
Citation
Charles Flexner. HIV drug development: the next 25 years. Nature Reviews Drug Discovery. 2007. 6: 959-66.Year
2007
Journal
Nature Reviews Drug Discovery
Hidden Markov models for settings with interval-censored transition times and uncertain time origin: application to HIV genetic analyses
Citation
B. Healy, Victor DeGruttola. Hidden Markov models for settings with interval-censored transition times and uncertain time origin: application to HIV genetic analyses. Biostatistics. 2007. 8: 438-52.Year
2007
Journal
Biostatistics
Systematic evaluation of allele-specific real-time PCR for the detection of minor HIV-1 variants with pol and env resistance mutations
Citation
Roger Paredes, Vincent C. Marconi, Thomas B. Campbell, Daniel R. Kuritzkes. Systematic evaluation of allele-specific real-time PCR for the detection of minor HIV-1 variants with pol and env resistance mutations. Journal of Virological Methods. 2007. 146: 136-46.Year
2007
Journal
Journal of Virological Methods
A comparison of three initial antiretroviral AIDS regimens
Citation
Heather Ribaudo, Daniel R. Kuritzkes, Roy (Trip) Gulick. A comparison of three initial antiretroviral AIDS regimens. New England Journal of Medicine. 2007. 357: 1056-7.Year
2007
Journal
New England Journal of Medicine
When and how can endpoints be changed after initiation of a randomized clinical trial?
Citation
Scott Evans. When and how can endpoints be changed after initiation of a randomized clinical trial?. Public Library of Science Clinical Trials. 2007. 2: e18.Year
2007
Journal
Public Library of Science Clinical Trials
Minorities, the poor and survivors of abuse: HIV-infected patients in the US deep south
Citation
Brian Wells Pence, Susan Reif, Kathryn Whetten, Jane Leserman, Dalene Stangl, Marvin Swartz, Nathan Thielman, Michael J. Mugavero. Minorities, the poor and survivors of abuse: HIV-infected patients in the US deep south. Journal of the Southern Medical Association. 2007. 100: 1114-22.Year
2007
Journal
Journal of the Southern Medical Association
Predicting CD4 lymphocyte count <200 cells/mm3 in an HIV type 1-infected African population
Citation
Susan C. Morpeth, John A. Crump, Humphrey J. Shao, Habib O. Ramadhani, Peter R. Kisenge, Cindy A. Moylan, Susanna Naggie, L. Brett Caram, Keren Z. Landman, Noel E. Sam, Dafrosa K. Itemba, John F. Shao, John Alexander Bartlett, Nathan Thielman. Predicting CD4 lymphocyte count <200 cells/mm3 in an HIV type 1-infected African population. AIDS Research and Human Retroviruses. 2007. 23: 1230-6.Year
2007
Journal
AIDS Research and Human Retroviruses
Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study
Citation
Sharon L. Shriver, Linda L. Millar, Giovanni Schifitto, Dodi Colquhoun, Bradford A. Navia, Robert Lenkinski, Constantin Yiannoutsos, R.Gilberto Gonzalez, Christina M. Marra, Stuart A. Lipton, Linda Chang, Thomas Ernst, Jeffrey G. Jarvik, Eric N. Miller, Elyse J. Singer, Ronald J. Ellis, Dennis Kolson, David M. Simpson, Avindra Nath, Joseph R. Berger. Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. AIDS. 2007. 21: 1877-86.Year
2007
Journal
AIDS
Non-nucleoside phenotypic hypersusceptibility cut-point determination from ACTG 359
Citation
Richard H. Haubrich, Hongyu Jiang, Ronald Swanstrom, Michael P. Bates, David Katzenstein, Leslie A. Petch, Courtney V. Fletcher, Susan A. Fiscus, Roy (Trip) Gulick. Non-nucleoside phenotypic hypersusceptibility cut-point determination from ACTG 359. HIV Clinical Trials. 2007. 8: 63-7.Year
2007
Journal
HIV Clinical Trials
Effect of antiretroviral therapy and hepatitis C co-infection on changes in lipid levels in HIV-infected patients 48 weeks after initiation of therapy
Citation
Jack T. Stapleton, Kara Bennett, Ronald J. Bosch, Philip M. Polgreen, Susan Swindells. Effect of antiretroviral therapy and hepatitis C co-infection on changes in lipid levels in HIV-infected patients 48 weeks after initiation of therapy. HIV Clinical Trials. 2007. 8: 429-36.Year
2007
Journal
HIV Clinical Trials